Key result
Clinical biomarkers and plasma proteomics predict incident cardiovascular-kidney-liver-metabolic disease with 0.78 AUC.
Why the study?
Traditional risk models for cardiovascular-kidney-liver-metabolic disease often yield miscalibrated or unstable predictions, particularly in data-sparse regions.
Does integrating clinical biomarkers and plasma proteomics improve uncertainty-calibrated risk prediction for cardiovascular-kidney-liver-metabolic disease?
Cohort (n=49,312)
Does integrating clinical biomarkers and plasma proteomics improve uncertainty-calibrated risk prediction for cardiovascular-kidney-liver-metabolic disease?
Answers are grounded in this paper and cite their sources.
Integrating clinical and proteomic data with machine learning provides accurate, uncertainty-calibrated risk estimates for cardiovascular-kidney-liver-metabolic disease.
Introduction and Objective: Cardiovascular-kidney-liver-metabolic (CKLM) disease reflects an interconnected network of metabolic organ dysfunction. Traditional risk models often yield miscalibrated or unstable predictions, particularly in data-sparse regions. We aimed to integrate clinical biomarkers and large-scale plasma proteomics to develop an uncertainty-aware CKLM risk prediction framework and identify key risk factors using machine learning with conformal inference. Methods: We analyzed 49,312 UK Biobank participants with proteomic profiling. The primary CKLM outcome was the first occurrence of chronic kidney disease, cardiovascular disease, type 2 diabetes, or metabolic dysfunction-associated steatotic liver disease. We used an 80/20 stratified split, selected top clinical and proteomic predictors via cross-validated random forest, benchmarked multiple classifiers, and applied J+aB conformal inference for uncertainty-calibrated risk prediction. Cox models estimated hazard ratios for top proteins, supplemented by pathway enrichment and correlation analyses. Results: Over a median 12.3-year follow-up, 9,787 participants developed CKLM. The final model achieved an area under the ROC curve of 0.78 and an average precision of 0.52, with consistent performance across sex, age, and ethnicity (AUC range 0.74-0.82). At 90% nominal confidence, prediction intervals showed 89.6% empirical coverage with a mean width of 0.085. Key clinical predictors included HbA1c, cystatin C, and waist-to-hip ratio; top proteomic predictors included GDF15, HAVCR1, and EDA2R. All selected proteins except PON3 were positively associated with CKLM risk, and enrichment analyses implicated inflammatory, and metabolic pathways. Conclusion: Integrating clinical and proteomic data with J+aB conformal inference provides accurate, uncertainty-calibrated CKLM risk estimates and mechanistic insights, supporting earlier identification of high-risk individuals and advancing precision prevention.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a cohort in Cardiovascular-kidney-liver-metabolic (CKLM) disease (n=49,312). Clinical biomarkers and plasma proteomics was evaluated on First occurrence of chronic kidney disease, cardiovascular disease, type 2 diabetes, or metabolic dysfunction-associated steatotic liver disease. Integrating clinical biomarkers and plasma proteomics achieved an area under the ROC curve of 0.78 for predicting incident cardiovascular-kidney-liver-metabolic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: